Regeneration Biomedical's Stem Cell Therapy Shows Promise in Alzheimer's Phase 1 Trial
• Regeneration Biomedical's RB-ADSCs stem cell therapy was well-tolerated in a Phase 1 trial for Alzheimer's disease.
• The therapy led to reduced levels of p-Tau and amyloid-beta in the cerebrospinal fluid of patients after 12 weeks.
• Two out of three patients showed improvement in Mini-Mental State Examination (MMSE) scores, indicating cognitive benefits.
• The trial's findings support further investigation of Wnt-activated stem cells for Alzheimer's, with enrollment ongoing for additional dose cohorts.
© Copyright 2025. All Rights Reserved by MedPath